JP2018536390A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536390A5 JP2018536390A5 JP2018517357A JP2018517357A JP2018536390A5 JP 2018536390 A5 JP2018536390 A5 JP 2018536390A5 JP 2018517357 A JP2018517357 A JP 2018517357A JP 2018517357 A JP2018517357 A JP 2018517357A JP 2018536390 A5 JP2018536390 A5 JP 2018536390A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- eukaryotic cell
- seq
- trc1
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131109A JP2022000019A (ja) | 2015-10-05 | 2021-08-11 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2023133416A JP2023175698A (ja) | 2015-10-05 | 2023-08-18 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2025092415A JP2025143265A (ja) | 2015-10-05 | 2025-06-03 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237382P | 2015-10-05 | 2015-10-05 | |
| US62/237,382 | 2015-10-05 | ||
| US201662297445P | 2016-02-19 | 2016-02-19 | |
| US62/297,445 | 2016-02-19 | ||
| PCT/US2016/055472 WO2017062439A1 (en) | 2015-10-05 | 2016-10-05 | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131109A Division JP2022000019A (ja) | 2015-10-05 | 2021-08-11 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536390A JP2018536390A (ja) | 2018-12-13 |
| JP2018536390A5 true JP2018536390A5 (https=) | 2019-11-14 |
| JP6929837B2 JP6929837B2 (ja) | 2021-09-15 |
Family
ID=57184827
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517357A Active JP6929837B2 (ja) | 2015-10-05 | 2016-10-05 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2021131109A Pending JP2022000019A (ja) | 2015-10-05 | 2021-08-11 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2023133416A Pending JP2023175698A (ja) | 2015-10-05 | 2023-08-18 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2025092415A Pending JP2025143265A (ja) | 2015-10-05 | 2025-06-03 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131109A Pending JP2022000019A (ja) | 2015-10-05 | 2021-08-11 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2023133416A Pending JP2023175698A (ja) | 2015-10-05 | 2023-08-18 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2025092415A Pending JP2025143265A (ja) | 2015-10-05 | 2025-06-03 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10799535B2 (https=) |
| EP (3) | EP3359660B1 (https=) |
| JP (4) | JP6929837B2 (https=) |
| AU (4) | AU2016333886B2 (https=) |
| CA (1) | CA3001008A1 (https=) |
| DK (2) | DK3359660T3 (https=) |
| ES (2) | ES2883116T3 (https=) |
| WO (1) | WO2017062439A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117070468A (zh) | 2015-10-05 | 2023-11-17 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
| EP3359660B1 (en) * | 2015-10-05 | 2019-12-04 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| CN109415687A (zh) * | 2016-04-07 | 2019-03-01 | 蓝鸟生物公司 | 嵌合抗原受体t细胞组合物 |
| US11377637B2 (en) | 2016-04-15 | 2022-07-05 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
| CA3068465A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| US20200239544A1 (en) * | 2017-10-03 | 2020-07-30 | Precision Biosciences, Inc. | Modified epidermal growth factor receptor peptides for use in genetically-modified cells |
| KR102503130B1 (ko) * | 2017-10-27 | 2023-02-24 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 내인성 t 세포 수용체의 표적화된 대체 |
| MX2020004541A (es) * | 2017-10-30 | 2021-04-12 | Pact Pharma Inc | Edicion de genes de celulas primarias. |
| US20200299658A1 (en) * | 2017-11-01 | 2020-09-24 | Precision Biosciences, Inc. | Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a |
| SG11202009761YA (en) | 2018-04-02 | 2020-10-29 | Pact Pharma Inc | Peptide-mhc compacts |
| CA3095795A1 (en) * | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
| US12467077B2 (en) * | 2018-11-19 | 2025-11-11 | Altius Institute For Biomedical Sciences | Compositions and methods for DNA modification detection |
| US20220017863A1 (en) * | 2019-02-08 | 2022-01-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Sirt2-ablated chimeric t cells |
| IL316576A (en) | 2019-02-12 | 2024-12-01 | Pact Pharma Inc | Preparations and methods for identifying antigen-specific T cells |
| WO2020205759A1 (en) * | 2019-03-29 | 2020-10-08 | Pact Pharma, Inc. | Personalized neoantigen-specific adoptive cell therapies |
| JP7286796B2 (ja) | 2019-04-03 | 2023-06-05 | プレシジョン バイオサイエンシズ，インク． | マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞 |
| CA3137975A1 (en) | 2019-05-07 | 2020-11-12 | Precision Biosciences, Inc. | Optimization of engineered meganucleases for recognition sequences |
| EP4004216A1 (en) | 2019-07-25 | 2022-06-01 | Precision BioSciences, Inc. | Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus |
| AU2020333851A1 (en) | 2019-08-20 | 2022-03-31 | Precision Biosciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
| CN114555788A (zh) * | 2019-09-06 | 2022-05-27 | 阿维塔斯有限公司 | 免疫细胞工程化用于体外细胞治疗 |
| WO2021087305A1 (en) | 2019-10-30 | 2021-05-06 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
| WO2021091935A1 (en) * | 2019-11-05 | 2021-05-14 | Lonza Walkersville, Inc. | Allogeneic t-cells and methods for production thereof |
| EP4069285A1 (en) | 2019-12-06 | 2022-10-12 | Precision BioSciences, Inc. | Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells |
| US20230183664A1 (en) | 2020-05-11 | 2023-06-15 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| WO2022035793A1 (en) | 2020-08-10 | 2022-02-17 | Precision Biosciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
| WO2022165111A1 (en) | 2021-01-28 | 2022-08-04 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| CA3173245A1 (en) * | 2021-04-22 | 2022-10-22 | James Jefferson Smith | Engineered meganucleases that target human mitochondrial genomes |
| WO2023064872A1 (en) | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| WO2023081767A1 (en) | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
| EP4460334A1 (en) | 2022-01-07 | 2024-11-13 | Precision BioSciences, Inc. | Optimized polynucleotides for protein expression |
| WO2024148167A1 (en) | 2023-01-05 | 2024-07-11 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene |
| WO2024236547A1 (en) | 2023-05-18 | 2024-11-21 | Inceptor Bio, Llc | Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof |
| WO2025046513A1 (en) | 2023-08-29 | 2025-03-06 | Inceptor Bio, Llc | Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof |
| WO2026047626A1 (en) | 2024-08-30 | 2026-03-05 | Inceptor Bio, Llc | Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
| US20100151556A1 (en) | 2002-03-15 | 2010-06-17 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| CA2891996A1 (en) | 2005-10-18 | 2007-04-26 | Duke University | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| EP2215223B1 (en) | 2007-10-31 | 2013-05-01 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| EP2329017A2 (en) | 2008-08-04 | 2011-06-08 | Cellectis | Novel method to generate meganucleases with altered characteristics |
| EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| CA2993567C (en) * | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| DK2714936T3 (en) | 2011-06-01 | 2019-03-25 | Prec Biosciences Inc | METHODS AND PRODUCTS FOR PRODUCING MANIPULATED MAMMAL CELL LINES WITH AMPLIFIED TRANSGENES |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| KR20140019635A (ko) | 2012-08-06 | 2014-02-17 | 엘지이노텍 주식회사 | 발광 소자 및 발광 소자 패키지 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| JP6346266B2 (ja) | 2013-03-21 | 2018-06-20 | サンガモ セラピューティクス， インコーポレイテッド | 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するｔ細胞受容体遺伝子の標的化された破壊 |
| AU2014248119B2 (en) | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
| US11311575B2 (en) | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| US10000746B2 (en) | 2013-05-31 | 2018-06-19 | Cellectis | LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof |
| JP6488283B2 (ja) | 2013-05-31 | 2019-03-20 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｃ−ｃケモカイン受容体５型（ｃｃｒ５）遺伝子を開裂するｌａｇｌｉｄａｄｇホーミングエンドヌクレアーゼおよびその用途 |
| CN105899665B (zh) | 2013-10-17 | 2019-10-22 | 桑格摩生物科学股份有限公司 | 用于核酸酶介导的基因组工程改造的递送方法和组合物 |
| ES3063961T3 (en) | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| MX373460B (es) * | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| CA2942268A1 (en) * | 2014-03-12 | 2015-09-17 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
| WO2015167766A1 (en) | 2014-04-29 | 2015-11-05 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies |
| RS60359B1 (sr) | 2014-06-06 | 2020-07-31 | Regeneron Pharma | Postupci i kompozicije za modifikovanje ciljanog lokusa |
| CA2959428A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| WO2016069282A1 (en) | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
| KR20260048600A (ko) | 2015-03-27 | 2026-04-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 변형된 t 세포 및 이의 제조 및 사용 방법 |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| EP3322297B1 (en) | 2015-07-13 | 2024-12-04 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| CN117070468A (zh) | 2015-10-05 | 2023-11-17 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
| EP3359660B1 (en) | 2015-10-05 | 2019-12-04 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| WO2017070429A1 (en) | 2015-10-22 | 2017-04-27 | Regents Of The University Of Minnesota | Methods involving editing polynucleotides that encode t cell receptor |
| EP3988655A3 (en) * | 2015-12-23 | 2022-08-03 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| MX2018010924A (es) | 2016-03-11 | 2019-02-13 | Bluebird Bio Inc | Células efectoras inmunitarias con edición genómica. |
| US11377637B2 (en) | 2016-04-15 | 2022-07-05 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
| CA3068465A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| CA3095795A1 (en) | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
-
2016
- 2016-10-05 EP EP16785045.2A patent/EP3359660B1/en active Active
- 2016-10-05 EP EP19212310.7A patent/EP3680329B1/en active Active
- 2016-10-05 ES ES19212310T patent/ES2883116T3/es active Active
- 2016-10-05 CA CA3001008A patent/CA3001008A1/en active Pending
- 2016-10-05 DK DK16785045.2T patent/DK3359660T3/da active
- 2016-10-05 WO PCT/US2016/055472 patent/WO2017062439A1/en not_active Ceased
- 2016-10-05 JP JP2018517357A patent/JP6929837B2/ja active Active
- 2016-10-05 AU AU2016333886A patent/AU2016333886B2/en active Active
- 2016-10-05 DK DK19212310.7T patent/DK3680329T3/da active
- 2016-10-05 ES ES16785045T patent/ES2768984T3/es active Active
- 2016-10-05 EP EP21177206.6A patent/EP3940070A1/en active Pending
- 2016-10-05 US US15/766,290 patent/US10799535B2/en active Active
-
2020
- 2020-09-09 US US17/016,056 patent/US11266693B2/en active Active
- 2020-12-15 AU AU2020289750A patent/AU2020289750B2/en active Active
-
2021
- 2021-08-11 JP JP2021131109A patent/JP2022000019A/ja active Pending
-
2022
- 2022-01-31 US US17/589,594 patent/US20220152112A1/en not_active Abandoned
-
2023
- 2023-04-03 AU AU2023202022A patent/AU2023202022A1/en not_active Abandoned
- 2023-08-18 JP JP2023133416A patent/JP2023175698A/ja active Pending
-
2024
- 2024-08-02 US US18/793,199 patent/US20240382526A1/en active Pending
-
2025
- 2025-06-03 JP JP2025092415A patent/JP2025143265A/ja active Pending
- 2025-11-24 AU AU2025271174A patent/AU2025271174A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018536390A5 (https=) | ||
| JP2018535663A5 (https=) | ||
| US11268065B2 (en) | Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene | |
| US20220152112A1 (en) | Nucleic acids encoding engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene | |
| US20220282285A1 (en) | Genetically-edited immune cells and methods of therapy | |
| KR20220016475A (ko) | 변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법 | |
| CN110139675A (zh) | 用具有工程化稳定的内源性foxp3基因表达的cd4 t细胞治疗自身免疫疾病的方法 | |
| KR20230157387A (ko) | Cas 효소를 이용한 다중 편집 | |
| HK40087901A (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
| HK40043947B (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
| HK40043947A (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
| HK1259673A1 (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
| HK1259673B (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |